Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.
Equine Vet J. 2009 Nov;41(8):772-7. doi: 10.2746/042516409x421624.
Detomidine hydrochloride is used to provide sedation, muscle relaxation and analgesia in horses, but a lack of information pertaining to plasma concentration has limited the ability to correlate drug concentration with effect.
To build on previous information and assess detomidine for i.v. and i.m. use in horses by simultaneously assessing plasma drug concentrations, physiological parameters and behavioural characteristics.
Systemic effects would be seen following i.m. and i.v. detomidine administration and these effects would be positively correlated with plasma drug concentrations.
Behavioural (e.g. head position) and physiological (e.g. heart rate) responses were recorded at fixed time points from 4 min to 24 h after i.m. or i.v. detomidine (30 microg/kg bwt) administration to 8 horses. Route of administration was assigned using a balanced crossover design. Blood was sampled at predetermined time points from 0.5 min to 48 h post administration for subsequent detomidine concentration measurements using liquid chromatography-mass spectrometry. Data were summarised as mean +/- s.d. for subsequent analysis of variance for repeated measures.
Plasma detomidine concentration peaked earlier (1.5 min vs. 1.5 h) and was significantly higher (105.4 +/- 71.6 ng/ml vs. 6.9 +/- 1.4 ng/ml) after i.v. vs. i.m. administration. Physiological and behavioural changes were of a greater magnitude and observed at earlier time points for i.v. vs. i.m. groups. For example, head position decreased from an average of 116 cm in both groups to a low value 35 +/- 23 cm from the ground 10 min following i.v. detomidine and to 64 +/- 24 cm 60 min after i.m. detomidine. Changes in heart rate followed a similar pattern; low value of 17 beats/min 10 min after i.v. administration and 29 beats/min 30 min after i.m. administration.
Plasma drug concentration and measured effects were correlated positively and varied with route of administration following a single dose of detomidine.
Results support a significant influence of route of administration on desirable and undesirable drug effects that influence case management.
盐酸右美托咪定用于马镇静、肌肉松弛和镇痛,但与药物浓度相关的信息有限,限制了将药物浓度与作用相关联的能力。
在先前信息的基础上,通过同时评估马静脉内和肌肉内给予右美托咪定的血浆药物浓度、生理参数和行为特征,评估其用于静脉内和肌肉内使用的情况。
肌肉内和静脉内给予右美托咪定会产生全身效应,这些效应与血浆药物浓度呈正相关。
在 8 匹马中,从肌肉内或静脉内给予右美托咪定(30μg/kg bwt)后 4 分钟至 24 小时,以固定时间点记录行为(例如头部位置)和生理(例如心率)反应。使用平衡交叉设计分配给药途径。在给药后 0.5 分钟至 48 小时内,以预定时间点采集血液样本,随后使用液相色谱-质谱法测量后续的右美托咪定浓度。数据以平均值±标准差表示,用于随后的重复测量方差分析。
与肌肉内给药相比,静脉内给药时右美托咪定的血浆浓度峰值更早(1.5 分钟 vs. 1.5 小时),且显著更高(105.4±71.6ng/ml vs. 6.9±1.4ng/ml)。静脉内与肌肉内组相比,生理和行为变化的幅度更大,且更早出现。例如,头部位置从两组的平均 116cm 下降到静脉内右美托咪定给药后 10 分钟的低值 35±23cm ,到肌肉内右美托咪定给药后 60 分钟的 64±24cm。心率的变化也遵循类似的模式;静脉内给药后 10 分钟出现低值 17 次/分钟,肌肉内给药后 30 分钟出现 29 次/分钟。
单次给予右美托咪定后,血浆药物浓度与测量的效应呈正相关,并与给药途径相关,存在差异。
结果支持给药途径对影响病例管理的理想和不理想药物作用的显著影响。